Overall, this PSMA-targeted nanosystem may provide a promising solution for the clinically-targeted treatment of PC using chemotherapeutic drugs and siRNA drugs that silence androgen-related signaling pathways. The gene discussed is FOLH1; the disease is pachyonychia congenita.